Arthralgia News and Research

RSS
Arthralgia is a symptom of injury, infection, illnesses - in particular arthritis - or an allergic reaction to medication. According to MeSH, the term "arthralgia" should only be used when the condition is non-inflammatory, and the term "arthritis" should be used when the condition is inflammatory.
Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

Anika Therapeutics announces positive results from CINGAL phase 3 trial for knee osteoarthritis

Anika Therapeutics announces positive results from CINGAL phase 3 trial for knee osteoarthritis

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

CSL Behring presents Phase I/III rVIII-SingleChain hemophilia A data at 2015 ISTH Congress

CSL Behring presents Phase I/III rVIII-SingleChain hemophilia A data at 2015 ISTH Congress

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015